Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: None
RT Other Mutations: P510A • K512Q • S513SG • S519N • Q520K • K527G • E529D • V531I • A534S • A554N

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: Q95K • S153A
IN Other Mutations: E11D • K14R • S24N • V31VI • K42KR • K46R • I60IL • I72V • K111R • T112I • I113V • T124A • T125A • G134N • K136Q • V201I • S230K • L234I • S283G

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Potential Low-Level Resistance
raltegravir (RAL)	Potential Low-Level Resistance

IN comments

Accessory

- **Q95K** is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility.
- S153Y/F are very rare mutations selected in vitro by EVG, DTG, BIC, and CAB. Alone they reduce EVG susceptibility about 5-fold and DTG, CAB, and BIC susceptibility about 2-fold. **S153A** is a rare mutation that alone does not appear to reduce INSTI susceptibility.

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of INSTI: Download CSV

Rule	BIC	CAB	DTG	EVG	RAL
Q95K	0	0	0	10	10